Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback